Treatment Of Opioid Use Disorder Among Commercially Insured US Adults, 2008-17

There is abundant literature on efforts to reduce opioid prescriptions and misuse, but comparatively little on the treatment provided to people with opioid use disorder (OUD). Using claims data representing 12-15 million nonelderly adults covered through commercial group insurance during the period...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Health affairs (Millwood, Va.) Ročník 39; číslo 6; s. 993 - 1001T
Hlavní autoři:	Shen, Karen, Barrette, Eric, Dafny, Leemore S
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States The People to People Health Foundation, Inc., Project HOPE 01.06.2020
Témata:	Adult Adults Age Age groups Aged Analgesics, Opioid - therapeutic use Cost analysis Drug addiction Drug overdose Drug use Drugs Efficacy Expenditures Group insurance Humans Insurance Insurance coverage Medicaid Medical treatment Mental disorders Mental health Methadone Narcotics Opiate Substitution Treatment Opioid-Related Disorders - drug therapy Opioid-Related Disorders - epidemiology Opioids Parity Patients Population Prescription drugs Prescriptions Substance abuse treatment Substance use disorder Treatment outcomes Trends Uninsured people United States United States United States > US Insurance claims Commercially insured Patient care Substance abuse Medication-assisted therapy Opioid use disorder Access and use Access to Care Prescription drugs Costs and spending Health policy Opioids Employer-sponsored insurance health conditions Pharmaceuticals
ISSN:	0278-2715, 2694-233X, 1544-5208, 2694-233X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	There is abundant literature on efforts to reduce opioid prescriptions and misuse, but comparatively little on the treatment provided to people with opioid use disorder (OUD). Using claims data representing 12-15 million nonelderly adults covered through commercial group insurance during the period 2008-17, we explored rates of OUD diagnoses, treatment patterns, and spending. We found three key patterns: The rate of diagnosed OUD nearly doubled during 2008-17, and the distribution has shifted toward older age groups; the likelihood that diagnosed patients will receive any treatment has declined, particularly among those ages forty-five and older, because of a reduction in the use of medication-assisted treatment (MAT) and despite clinical evidence demonstrating its efficacy; and treatment spending is lower for patients who choose MAT. These patterns suggest that policies supporting the use of MAT are critical to addressing the undertreatment of OUD among the commercially insured and that further research to assess the cost-effectiveness of treatment with versus without medication is needed.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	0278-2715 2694-233X 1544-5208 2694-233X
DOI:	10.1377/hlthaff.2019.01041